June pre quiz

Episode 8 - June (pre quiz)

Which KRAS mutation is most commonly found in NSCLC and is now a therapeutic target?(Required)
Which of the following best describes the mechanism of action of KRAS G12C inhibitors?(Required)
Which challenge is emerging in the management of KRAS G12C-mutant NSCLC?(Required)